Candriam Luxembourg S.C.A. lowered its position in Tesaro Inc. (NASDAQ:TSRO) by 42.0% during the second quarter, Holdings Channel reports. The fund owned 101,500 shares of the biopharmaceutical company’s stock after selling 73,500 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Tesaro were worth $8,531,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Smith Asset Management Group LP bought a new stake in shares of Tesaro during the second quarter worth about $406,000. Parametrica Management Ltd boosted its stake in shares of Tesaro by 144.9% in the second quarter. Parametrica Management Ltd now owns 13,988 shares of the biopharmaceutical company’s stock worth $1,176,000 after buying an additional 8,277 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new stake in Tesaro during the second quarter valued at $941,000. venBio Select Advisor LLC acquired a new stake in Tesaro during the first quarter valued at $6,605,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Tesaro by 15.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 18,369 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 2,500 shares in the last quarter. 88.81% of the stock is owned by hedge funds and other institutional investors.
Tesaro Inc. (NASDAQ:TSRO) traded up 0.20% on Tuesday, reaching $108.04. The company’s stock had a trading volume of 642,300 shares. Tesaro Inc. has a 12 month low of $29.51 and a 12 month high of $110.48. The company’s market cap is $5.55 billion. The company has a 50-day moving average price of $95.00 and a 200 day moving average price of $66.01.
Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.43. The firm earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same period in the prior year, the company posted ($1.51) EPS. On average, equities research analysts anticipate that Tesaro Inc. will post ($7.36) EPS for the current fiscal year.
Several equities research analysts have recently weighed in on the company. SunTrust Banks Inc. reissued a “buy” rating and issued a $91.60 price objective on shares of Tesaro in a research report on Wednesday, September 14th. Royal Bank Of Canada assumed coverage on Tesaro in a research report on Friday, August 12th. They issued an “outperform” rating and a $122.00 price objective for the company. RBC Capital Markets assumed coverage on Tesaro in a research report on Friday, August 12th. They issued an “outperform” rating and a $122.00 price objective for the company. Citigroup Inc. increased their price objective on Tesaro from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, August 8th. Finally, FBR & Co reissued a “buy” rating on shares of Tesaro in a research report on Tuesday, September 13th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Tesaro has a consensus rating of “Buy” and a consensus price target of $94.40.
In other news, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the completion of the transaction, the vice president now owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total value of $44,112.96. Following the transaction, the senior vice president now directly owns 1,250 shares of the company’s stock, valued at approximately $135,150. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tesaro Inc. (NASDAQ:TSRO).
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.